TW202045495A - １－（１－側氧基－１，２－二氫異喹啉－５－基）－５－（三氟甲基）－ｎ－（２－（三氟甲基）吡啶－４－基）－１ｈ－吡唑－４－甲醯胺一水合物的結晶形式 - Google Patents

１－（１－側氧基－１，２－二氫異喹啉－５－基）－５－（三氟甲基）－ｎ－（２－（三氟甲基）吡啶－４－基）－１ｈ－吡唑－４－甲醯胺一水合物的結晶形式 Download PDF

Info

Publication number
TW202045495A
TW202045495A TW109105620A TW109105620A TW202045495A TW 202045495 A TW202045495 A TW 202045495A TW 109105620 A TW109105620 A TW 109105620A TW 109105620 A TW109105620 A TW 109105620A TW 202045495 A TW202045495 A TW 202045495A
Authority
TW
Taiwan
Prior art keywords
crystalline form
compound
cancer
disorder
disease
Prior art date
Application number
TW109105620A
Other languages
English (en)
Chinese (zh)
Inventor
卡莉娜 雷茲
克里斯托弗 金普
羅伯特 吉爾特曼
魏昊娟
周鵬
Original Assignee
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商健生藥品公司 filed Critical 比利時商健生藥品公司
Publication of TW202045495A publication Critical patent/TW202045495A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW109105620A 2019-02-22 2020-02-21 １－（１－側氧基－１，２－二氫異喹啉－５－基）－５－（三氟甲基）－ｎ－（２－（三氟甲基）吡啶－４－基）－１ｈ－吡唑－４－甲醯胺一水合物的結晶形式 TW202045495A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/CN2019/075834 2019-02-22
CN2019075834 2019-02-22

Publications (1)

Publication Number Publication Date
TW202045495A true TW202045495A (zh) 2020-12-16

Family

ID=69723907

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109105620A TW202045495A (zh) 2019-02-22 2020-02-21 １－（１－側氧基－１，２－二氫異喹啉－５－基）－５－（三氟甲基）－ｎ－（２－（三氟甲基）吡啶－４－基）－１ｈ－吡唑－４－甲醯胺一水合物的結晶形式

Country Status (21)

Country Link
US (1) US12269813B2 (enExample)
EP (1) EP3927696B1 (enExample)
JP (1) JP2022523368A (enExample)
KR (1) KR20210131371A (enExample)
CN (1) CN113474339B (enExample)
AU (1) AU2020226723B2 (enExample)
BR (1) BR112021016400A2 (enExample)
CA (1) CA3129623A1 (enExample)
EA (1) EA202192320A1 (enExample)
EC (1) ECSP21067828A (enExample)
ES (1) ES2966132T3 (enExample)
IL (1) IL285675A (enExample)
JO (1) JOP20210227A1 (enExample)
MA (1) MA55019A (enExample)
MX (1) MX2021010133A (enExample)
PE (1) PE20212067A1 (enExample)
PH (1) PH12021552018A1 (enExample)
SG (1) SG11202108909SA (enExample)
TW (1) TW202045495A (enExample)
UY (1) UY38592A (enExample)
WO (1) WO2020169736A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
BR112023003106A2 (pt) 2020-08-21 2023-04-04 Janssen Pharmaceutica Nv Forma amorfa de um inibidor de malt1 e formulações do mesmo
BR112023017689A2 (pt) 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Método de tratamento de uma condição com o uso de uma dose terapeuticamente eficaz do inibidor de malt1 jnj-67856633 (1-(1-oxo-1,2-di-hidroisoquinolin-5-il)-5-(trifluorometil)-n­(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida)
EP4301365A1 (en) 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
AU2022326183A1 (en) * 2021-08-09 2024-03-28 Janssen Pharmaceutica Nv Compositions for use in treating b-cell malignancies
WO2025073968A1 (en) 2023-10-06 2025-04-10 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525183A (ja) 2003-04-30 2007-09-06 アジェンシス， インコーポレイテッド 癌の処置および検出において有用な１０９ｐ１ｄ４と称される、核酸および対応タンパク質
WO2007111904A2 (en) * 2006-03-22 2007-10-04 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
WO2008092292A1 (en) 2007-01-17 2008-08-07 The Hong Kong University Of Science And Technology Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2
WO2011036885A1 (ja) * 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
KR101580714B1 (ko) 2010-06-03 2016-01-04 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도
CN102947270B (zh) 2010-06-22 2015-04-08 巴斯夫欧洲公司 制备4-羟基吡啶的方法
MX2014014531A (es) * 2012-05-31 2015-04-08 Hoffmann La Roche Derivados de aminoquinazolina y piridopirimidina.
HUE044351T2 (hu) 2014-05-28 2019-10-28 Novartis Ag Új pirazolo-pirimidin származékok és azok alkalmazása MALT1 inhibitorként
EP3177366A4 (en) 2014-08-08 2018-04-04 Pharmacyclics LLC Bruton's tyrosine kinase inhibitor combinations and uses thereof
US10835524B2 (en) * 2015-06-24 2020-11-17 University Of Florida Research Foundation, Incorporated Compositions for the treatment of pancreatic cancer and uses thereof
CA3003820A1 (en) 2015-11-13 2017-05-18 Novartis Ag Novel pyrazolo pyrimidine derivatives
EP3423452B1 (en) 2016-03-01 2025-05-07 University of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
EP3576744A1 (en) 2017-02-01 2019-12-11 Medivir Aktiebolag Therapeutic applications of malt1 inhibitors
US11571427B2 (en) 2017-12-28 2023-02-07 The General Hospital Corporation Targeting the CBM signalosome complex induces regulatory T cells to inflame the tumor microenvironment
WO2019161921A1 (de) 2018-02-23 2019-08-29 Industrieanlagen-Betriebsgesellschaft Mbh Vorrichtung zum erzeugen eines magnetfelds, insbesondere für ein induktives ladesystem, und primäreinrichtung eines induktiven ladesystems zum dynamischen aufladen von fahrzeugen
WO2021138298A1 (en) 2019-12-30 2021-07-08 Rheos Medicines, Inc. Malt1 modulators and uses thereof
BR112023003106A2 (pt) * 2020-08-21 2023-04-04 Janssen Pharmaceutica Nv Forma amorfa de um inibidor de malt1 e formulações do mesmo

Also Published As

Publication number Publication date
CN113474339A (zh) 2021-10-01
US20220127249A1 (en) 2022-04-28
CA3129623A1 (en) 2020-08-27
EP3927696A1 (en) 2021-12-29
PH12021552018A1 (en) 2022-09-19
JOP20210227A1 (ar) 2023-01-30
IL285675A (en) 2021-10-31
WO2020169736A1 (en) 2020-08-27
ECSP21067828A (es) 2021-11-18
AU2020226723B2 (en) 2025-01-23
UY38592A (es) 2020-08-31
JP2022523368A (ja) 2022-04-22
CN113474339B (zh) 2025-02-25
SG11202108909SA (en) 2021-09-29
AU2020226723A1 (en) 2021-08-19
PE20212067A1 (es) 2021-10-26
ES2966132T3 (es) 2024-04-18
MX2021010133A (es) 2021-09-23
EP3927696B1 (en) 2023-10-18
EA202192320A1 (ru) 2021-11-16
MA55019A (fr) 2021-12-29
US12269813B2 (en) 2025-04-08
KR20210131371A (ko) 2021-11-02
BR112021016400A2 (pt) 2021-10-13
EP3927696C0 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
TW202045495A (zh) １－（１－側氧基－１，２－二氫異喹啉－５－基）－５－（三氟甲基）－ｎ－（２－（三氟甲基）吡啶－４－基）－１ｈ－吡唑－４－甲醯胺一水合物的結晶形式
CN114423750B (zh) 2,4-二取代嘧啶衍生物及其制备方法和用途
CN111770914B (zh) 作为神经激肽-1受体拮抗剂的化合物及其用途
CN105793245B (zh) 药物化合物
WO2019143730A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
CN114867531B (zh) Egfr抑制剂
CN101759693B (zh) 苯骈异恶唑哌啶衍生物及在制备镇痛、镇静药物中的应用
JP5924453B2 (ja) 二環式含窒素芳香族ヘテロ環アミド化合物
CN112759544B (zh) 3-(二甲氨基甲基)哌啶-4-醇衍生物制备方法和药物用途
WO2018072742A1 (zh) 一种咪唑并异吲哚类衍生物的游离碱的结晶形式及其制备方法
CN104169277B (zh) 极光激酶和flt3激酶调节剂
CN101993417A (zh) 磷酸二甲啡烷的稳定新晶型
HK40052643A (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
WO2023154338A1 (en) Solid forms of a parp14 inhibitor
EA045924B1 (ru) Кристаллическая форма моногидрата 1-(1-оксо-1,2-дигидроизохинолин-5-ил)-5-(трифторметил)-n-(2-(трифторметил)пиридин-4-ил)-1h-пиразол-4-карбоксамида
JP7565118B2 (ja) （ｓ，ｅ）－４－（ジメチルアミノ）－ｎ－（３－（４－（２－ヒドロキシ－１－フェネチルアミノ）－６－フェニルフロ［２，３－ｄ］ピリミジン－５－イル）フェニル）ブタ－２－エナミド遊離塩基の結晶形
TW201829398A (zh) 酪胺酸蛋白激酶調節劑、晶型及其用途
JP2025501195A (ja) アミノピリミジン系化合物の塩及びその用途
TW202342041A (zh) 一種藥物組合物及所含活性成分化合物的製備方法
CN118451071A (zh) 表皮生长因子受体抑制剂的结晶多晶型物及其组合物和方法
JP2024544019A (ja) 化合物
KR20210155806A (ko) Pi3k 저해제의 결정다형 및 이의 제조방법
WO2019001551A1 (zh) 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法